Sugi Predict

Sugi Predict / Compounds / SCHEMBL28711

SCHEMBL28711

SCHEMBL28711

COC(=O)C1CCSCC1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ CHRNB2 P17787 2/20 0.42
▸ CHRNA4 P43681 2/20 0.42
▸ CHRNB4 P30926 1/20 0.42
▸ CHRNA3 P32297 1/20 0.42
▸ CHRNA7 P36544 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ PPM1B O75688 1/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ PPP1CC P36873 1/20 0.39
▸ BRD4 O60885 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5425052 0.86 — —
SCHEMBL2200767 0.82 TP53 (0.56) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL2948892 0.82 TP53 (0.56) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL244740 0.82 — —
SCHEMBL74396 0.82 TP53 (0.56) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL8610883 0.79 TP53 (0.54) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
Hydrochloric Acid SCHEMBL6271997 0.79 — —
Methyl Alcohol SCHEMBL27845135 0.79 TP53 (0.54) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL2833747 0.77 SMN1; SMN2 (0.59) TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL18408 0.77 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4704830-A2 MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF Septerna, Inc. (US) 2026-03-11 — — EP disclosed
WO-2025064683-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 — — WO disclosed
EP-3645533-B1 TDO2 AND IDO1 INHIBITORS GENENTECH INC (US) 2025-03-26 — — EP disclosed
WO-2025059027-A1 CYCLOPENTA[E]PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS MALT1 INHIBITORS SCHRÖDINGER, INC. (US) 2025-03-20 — — WO disclosed
US-20250091989-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-20 — — US disclosed
CN-119161372-A Bimetallic compound based on hydrazide pyrene skeleton, and preparation method and application thereof 万华化学集团股份有限公司 2024-12-20 — — CN disclosed
WO-2024226914-A2 MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF SEPTERNA, INC. (US) 2024-10-31 — — WO disclosed
US-11603373-B2 TDO2 and IDO1 inhibitors GENENTECH, INC. (US) 2023-03-14 — — US disclosed
US-20230036854-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS THE UNIVERSITY OF SHEFFIELD (GB) 2023-02-02 — — US disclosed
EP-3878451-A1 PHARMACEUTICAL COMPOSITION COMPRISING A JAK-INHIBITING 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINE COMPOUND Array Biopharma Inc. (US) 2021-09-15 — — EP disclosed
WO-2012027234-A1 FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN SCHERING CORPORATION (US) 2012-03-01 — — WO disclosed
WO-2012027234-A1 FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN SCHERING CORPORATION (US) 2012-03-01 — — WO disclosed
EP-2417138-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS Schering Corporation (US) 2012-02-15 — — EP disclosed
US-20100286171-A1 PHENYLACETAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-11-11 — — US disclosed
WO-2010118207-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS SCHERING CORPORATION (US) 2010-10-14 — — WO disclosed
WO-2010118207-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS SCHERING CORPORATION (US) 2010-10-14 — — WO disclosed
EP-2236498-A1 PHENYL ACETAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2010-10-06 — — EP disclosed
WO-2007124319-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 — — WO disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 — — US disclosed
WO-2006136917-A1 TRIAZOLYLPIPERIDINE DERIVATIVES AND USE THEREOF IN THERAPY PFIZER LIMITED (GB) 2006-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249680-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES TP53 184/4885SMN1; SMN2 2358/4885CHRNB2 2226/4885
US-20250091989-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS TP53 26/4885SMN1; SMN2 1694/4885CHRNB2 4822/4885
US-20100286171-A1 PHENYLACETAMIDE DERIVATIVE AADAC, PGC, PC TP53 3954/4885SMN1; SMN2 4100/4885CHRNB2 3364/4885
US-11603373-B2 TDO2 and IDO1 inhibitors IDO1, TDO2, IDO2 TP53 337/4885SMN1; SMN2 4143/4885CHRNB2 2474/4885
US-20230036854-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS MC2R, AGTR2, NR3C2 TP53 1140/4885SMN1; SMN2 1891/4885CHRNB2 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.